Our Pipeline.

Developing stabilized protein therapeutics with improved durability and consistent performance.

;

Therapeutic Pipeline

Our programs apply INCYPRO to address key limitations of biologics, short half-life, instability, and limited activity. Each candidate validates the therapeutic potential of our platform technology, support more effective treatment options.

Program Highlights

INCYPRO Asparaginase

A stabilized enzyme designed to reduce dosing frequency in ALL treatment. Preclinical studies have shown a 20-fold increase in serum half-life while retaining enzymatic activity.

Read more.

INCYPRO Galectin

A galectin engineered for stable anti-inflammatory effects. The program focuses on maintaining active conformation and reducing aggregation.

INCYPRO Proteins

Additional proteins in early evaluation, with a focus on oncology and immunomodulation.

Shared purpose. Stronger proteins.

We partner with companies who believe in pushing therapeutic performance further. Together, we apply INCYPRO to proprietary proteins and co-develop candidates built on stability, precision, and respect for nature’s design.